Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
May 1, 2026
Public Health Today—May 1, 2026
April 30, 2026
Vaccines Today—April 30, 2026
April 30, 2026
Respiratory Today—April 30, 2026
April 30, 2026
Cell and Gene Therapy Today—April 30, 2026
April 30, 2026
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
April 30, 2026
Rare Diseases Today—April 30, 2026
April 30, 2026
Cardiovascular Today—April 30, 2026
April 30, 2026
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
April 29, 2026
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
April 29, 2026
Women’s Health Today—April 29, 2026
April 29, 2026